[{"address1": "3940 Trust Way", "city": "Hayward", "state": "CA", "zip": "94545", "country": "United States", "phone": "510 780 0819", "website": "https://benitec.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.", "fullTimeEmployees": 16, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael  Graham", "title": "Head of Discovery & Founding Scientist", "fiscalYear": 2012, "totalPay": 131289, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Claudia  Kloth Ph.D.", "title": "Senior Vice President of Manufacturing", "fiscalYear": 2012, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1356912000, "maxAge": 86400, "priceHint": 2, "previousClose": 10.75, "open": 10.83, "dayLow": 10.55, "dayHigh": 10.83, "regularMarketPreviousClose": 10.75, "regularMarketOpen": 10.83, "regularMarketDayLow": 10.55, "regularMarketDayHigh": 10.83, "beta": 0.9, "forwardPE": -1.1210191, "volume": 13598, "regularMarketVolume": 13598, "averageVolume": 28628, "averageVolume10days": 36560, "averageDailyVolume10Day": 36560, "bid": 7.6, "ask": 13.79, "bidSize": 200, "askSize": 200, "marketCap": 214596112, "fiftyTwoWeekLow": 2.69, "fiftyTwoWeekHigh": 12.89, "fiftyDayAverage": 9.52522, "twoHundredDayAverage": 7.33291, "currency": "USD", "enterpriseValue": 60886488, "floatShares": 3878280, "sharesOutstanding": 19815000, "sharesShort": 38171, "sharesShortPriorMonth": 59077, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0021, "heldPercentInsiders": 0.04388, "heldPercentInstitutions": 0.45791999, "shortRatio": 0.98, "shortPercentOfFloat": 0.0025, "impliedSharesOutstanding": 20321600, "bookValue": 4.684, "priceToBook": 2.2544835, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -22370000, "trailingEps": -5.51, "forwardEps": -9.42, "lastSplitFactor": "1:17", "lastSplitDate": 1690329600, "enterpriseToEbitda": -2.718, "52WeekChange": 1.9252079, "SandP52WeekChange": 0.3464489, "lastDividendValue": 0.765, "lastDividendDate": 1527811200, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "BNTC", "underlyingSymbol": "BNTC", "shortName": "Benitec Biopharma Inc.", "longName": "Benitec Biopharma Inc.", "firstTradeDateEpochUtc": 1403616600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b3cc27a2-16b5-3a55-8f58-57577c96b7a7", "messageBoardId": "finmb_4492928", "gmtOffSetMilliseconds": -14400000, "currentPrice": 10.56, "targetHighPrice": 35.0, "targetLowPrice": 17.0, "targetMeanPrice": 24.0, "targetMedianPrice": 20.0, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 50866000, "totalCashPerShare": 4.819, "ebitda": -22403000, "totalDebt": 284000, "quickRatio": 10.377, "currentRatio": 10.494, "debtToEquity": 0.601, "returnOnAssets": -0.49604, "returnOnEquity": -0.9168, "freeCashflow": -11681250, "operatingCashflow": -19403000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-31"}]